Sol-Gel Technologies Ltd. Ordinary Shares (SLGL) Dividend History

Company News

• Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

  Sol-Gel Technologies reported financial results for Q2 2024, including a net income of $1.9 million. The company provided updates on its pipeline, including the ongoing Phase 3 trial for SGT-610 in Gorlin Syndrome and the proof-of-concept study for SGT-210 in Darier disease. Sol-Gel also announced licensing agreements for its approved products TWYNEO and EPSOLAY in Europe and South Africa.

  GlobeNewswire Inc.
• Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

  SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: ACB
• Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

  Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

  GlobeNewswire Inc.
• Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

  Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

  GlobeNewswire Inc.
• Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates

  Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: TSHA